Navigation Links
Professor Sander van Deventer Appointed to Supervisory Board of AMT
Date:5/6/2010

AMSTERDAM, The Netherlands, May 6, 2010 /PRNewswire-FirstCall/ --

- CFO Piers Morgan Appointed to Management Board

- All Resolutions Adopted by AGM

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that, at the Annual General Meeting (AGM) of the Company Professor Sander van Deventer has been appointed to the Supervisory Board.

Professor van Deventer is one of AMT's co-founders. He was Professor and Head of the Department of Experimental Medicine, Chairman at the Department of Gastroenterology of the AMC from 2002 to 2004, and subsequently Professor of Experimental Medicine at the University of Amsterdam Medical School until 2008. He has over 15 years experience in biotechnology product development. He is the author of more than 350 scientific articles in peer-reviewed journals and serves as an advisor to regulatory authorities including the EMA and FDA.

Professor van Deventer served on the Management Board of AMT as Chief Scientific Officer until February 2009, and temporarily also as Chief Executive Officer from February - October 2009. He currently chairs the Scientific Advisory Board of AMT. He is also a partner of Forbion Capital, a shareholder in the Company, and Professor of Translational Gastroenterology at the Leiden University Medical Center (LUMC).

As a result of Professor van Deventer's previous position as a member of the Management Board, among others, he is not independent within the meaning of provision III.2.2 of the Dutch Corporate Governance Code.

Also at the Annual General Meeting Mr Piers Morgan, CFO, was appointed to the Management Board and Mr Alexander Ribbink retired as a member of the Supervisory Board. All resolutions proposed to the Annual General Meeting, as set out in the Notice of General Meeting dated April 12, 2010, were approved unanimously.

Jörn Aldag CEO of AMT said:

"AMT is delighted that Sander van Deventer is joining the Supervisory Board. His contributions to the continued development of the Company have been and will be extremely valuable. We would also like to thank Alexander Ribbink for the support he has given to the Company during a period of significant progress and change for AMT."

About Amsterdam Molecular Therapeutics

AMT, founded in 1998 and based in Amsterdam, is a leader in the development of human gene based therapies. Using AAV as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This safe and efficacious proprietary platform offers a unique manufacturing capability which can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, DMD, Acute Intermittent Porphyria and Parkinson's Disease at different stages of research or development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Professor Steven Ley of University of Cambridge will Present Free Webinar, 'Application of the ReactIR Flow Cell to Continuous Processing Technology'
2. NTU assistant professor wins Young Scientist Award
3. NTU professor bags inaugural award honoring women in science
4. Professor Nancy Ip Joins aTyr Pharmas Scientific Advisory Board
5. Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
6. Brown engineering professor wins prestigious White House award
7. Professor Fisher receives ASEEs Beer and Johnston Award
8. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
9. Professor Wing Wong Elected to the National Academy of Sciences
10. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
11. University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):